SK285210B6
(en)
*
|
1996-10-11 |
2006-09-07 |
Scarista Limited |
A pharmaceutical preparation for the treatment of schizophrenia and use of an oil comprising eicosapentaenoic or stearidonic acid, or combination thereof in the manufacture of the medicament
|
JP2002501887A
(en)
*
|
1998-01-28 |
2002-01-22 |
ワーナー−ランバート・カンパニー |
How to treat Alzheimer's disease
|
US7138431B1
(en)
|
1998-02-23 |
2006-11-21 |
Wake Forest University |
Dietary control of arachidonic acid metabolism
|
US6107334A
(en)
|
1998-02-23 |
2000-08-22 |
Wake Forest University |
Dietary control of arachidonic acid metabolism
|
FR2788437B1
(en)
*
|
1999-01-14 |
2006-08-11 |
Inst Rech Biolog Sa |
NEW USE OF PLANT AND ANIMAL PHOSPHOLIPIDS IN NUTRITIONAL THERAPEUTICS
|
GB9901808D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Drugs for treatment of psychiatric and brain disorders
|
AU2006201772B2
(en)
*
|
1999-01-27 |
2010-02-04 |
Amarin Neuroscience Limited |
Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
GB9904895D0
(en)
*
|
1999-03-03 |
1999-04-28 |
Scarista Limited |
Regulators of coenzyme-A-independent transacylase as psychotropic drugs
|
EP1274444B1
(en)
*
|
2000-03-16 |
2013-05-15 |
THE McLEAN HOSPITAL CORPORATION |
Cdp-choline and uridine for the treatment of alcohol abuse
|
IL142535A0
(en)
*
|
2001-04-11 |
2002-03-10 |
Yeda Res & Dev |
Pharmaceutical compositions for the treatment of inflammation
|
IL142536A0
(en)
*
|
2001-04-11 |
2002-03-10 |
Yeda Res & Dev |
Carriers for therapeutic preparations for treatment of t-cell mediated diseases
|
WO2002092779A2
(en)
*
|
2001-05-17 |
2002-11-21 |
Pilot Therapeutics, Inc. |
Method for enriching tissues in long chain polyunsaturated fatty acids
|
DK1576970T3
(en)
|
2001-11-08 |
2010-07-12 |
Ziscoat N V |
Intraluminal device with a coating containing a therapeutic agent
|
NL1019368C2
(en)
|
2001-11-14 |
2003-05-20 |
Nutricia Nv |
Preparation for improving receptor performance.
|
US8987263B2
(en)
|
2002-10-10 |
2015-03-24 |
Meir Shinitzky |
Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
|
GB0311081D0
(en)
*
|
2003-05-14 |
2003-06-18 |
Btg Internat Limted |
Treatment of neurodegenerative conditions
|
DE112004001520B4
(en)
*
|
2003-08-18 |
2008-04-10 |
Btg International Ltd. |
Use of a lipid glyceride of specified structure for the manufacture of a medicament for the treatment of multiple sclerosis
|
JP2007508315A
(en)
*
|
2003-10-08 |
2007-04-05 |
ザ マクレーン ホスピタル コーポレーション |
Methods for treating mental disorders, substance abuse disorders, and other disorders using combinations comprising omega-3 fatty acids
|
WO2005034874A2
(en)
*
|
2003-10-08 |
2005-04-21 |
The Mclean Hospital Corporation |
Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
|
JP2007524674A
(en)
*
|
2004-01-19 |
2007-08-30 |
マーテック・バイオサイエンシーズ・コーポレーション |
Reelin deficiency or dysfunction and related methods
|
ITMI20040069A1
(en)
*
|
2004-01-21 |
2004-04-21 |
Tiberio Bruzzese |
USE OF HIGH CONCENTRATION N-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
|
US7022713B2
(en)
*
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
US20050266051A1
(en)
*
|
2004-05-27 |
2005-12-01 |
The Procter & Gamble Company |
Pet food compositions and methods
|
EP1765075A4
(en)
*
|
2004-06-10 |
2010-11-10 |
Mclean Hospital Corp |
Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
|
EP1765364A4
(en)
*
|
2004-06-10 |
2010-09-22 |
Mclean Hospital Corp |
Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
|
US7947661B2
(en)
*
|
2004-08-11 |
2011-05-24 |
The Mclean Hospital Corporation |
Compounds for the treatment of marihuana dependence, withdrawal, and usage
|
EP1812022B1
(en)
|
2004-09-28 |
2014-01-15 |
Atrium Medical Corporation |
Stand-alone film and methods for making the same
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US20060083768A1
(en)
*
|
2004-09-28 |
2006-04-20 |
Atrium Medical Corporation |
Method of thickening a coating using a drug
|
US8312836B2
(en)
|
2004-09-28 |
2012-11-20 |
Atrium Medical Corporation |
Method and apparatus for application of a fresh coating on a medical device
|
US9801982B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Implantable barrier device
|
US20090011116A1
(en)
*
|
2004-09-28 |
2009-01-08 |
Atrium Medical Corporation |
Reducing template with coating receptacle containing a medical device to be coated
|
EP1804717A4
(en)
|
2004-09-28 |
2015-11-18 |
Atrium Medical Corp |
Drug delivery coating for use with a stent
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US8367099B2
(en)
|
2004-09-28 |
2013-02-05 |
Atrium Medical Corporation |
Perforated fatty acid films
|
US7550286B2
(en)
*
|
2004-11-04 |
2009-06-23 |
E. I. Du Pont De Nemours And Company |
Docosahexaenoic acid producing strains of Yarrowia lipolytica
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
BRPI0516803A
(en)
*
|
2004-11-19 |
2008-09-23 |
Martek Biosciences Corp |
long chain polyunsaturated fatty acid oxylipines and their methods of production and use
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
GB0425932D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Btg Int Ltd |
Structured phospholipids
|
GB2421909A
(en)
*
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
GB0504362D0
(en)
|
2005-03-02 |
2005-04-06 |
Btg Int Ltd |
Cytokine modulators
|
GB0504333D0
(en)
*
|
2005-03-02 |
2005-04-06 |
Btg Int Ltd |
Treatment of cytokine dysregulation
|
CN101262863B
(en)
*
|
2005-07-08 |
2016-08-31 |
Dsmip资产公司 |
For treating the polyunsaturated fatty acid of dull-witted and front dull-witted associated conditions
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US9278161B2
(en)
|
2005-09-28 |
2016-03-08 |
Atrium Medical Corporation |
Tissue-separating fatty acid adhesion barrier
|
US8574627B2
(en)
|
2006-11-06 |
2013-11-05 |
Atrium Medical Corporation |
Coated surgical mesh
|
CA2626030A1
(en)
|
2005-10-15 |
2007-04-26 |
Atrium Medical Corporation |
Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
|
ES2511772T3
(en)
*
|
2005-12-20 |
2014-10-23 |
Cenestra, Llc |
Omega-3 fatty acid formulations
|
US20090320148A1
(en)
*
|
2006-01-31 |
2009-12-24 |
Martek Biosciences Corporation |
Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
|
US9492596B2
(en)
|
2006-11-06 |
2016-11-15 |
Atrium Medical Corporation |
Barrier layer with underlying medical device and one or more reinforcing support structures
|
US20100130611A1
(en)
*
|
2006-12-20 |
2010-05-27 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
JP2010519311A
(en)
*
|
2007-02-20 |
2010-06-03 |
マーテック バイオサイエンシーズ コーポレーション |
Oxylipins derived from long-chain polyunsaturated fatty acids and their preparation and methods of use
|
EP2117301A4
(en)
*
|
2007-02-26 |
2010-04-14 |
Yeda Res & Dev |
Use of long-chain alcohol derivatives for the treatment of alopecia areata
|
US7964751B2
(en)
*
|
2007-02-26 |
2011-06-21 |
Yeda Research And Development Co. Ltd. |
Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
|
CN101970638B
(en)
|
2007-10-03 |
2015-02-11 |
纳幕尔杜邦公司 |
Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
|
CA2704371A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Wake Forest University School Of Medicine |
Compositions and methods for prevention and treatment of mammalian diseases
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
WO2009086281A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
US20100041621A1
(en)
*
|
2008-08-15 |
2010-02-18 |
Perry Renshaw |
Methods and compositions for improving cognitive performance
|
EP2334295B1
(en)
|
2008-09-02 |
2017-06-28 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
AU2015203289B2
(en)
*
|
2008-09-09 |
2017-03-16 |
Orygen Research Centre |
Prevention of psychotic disorders and/or treatment of psychotic symptoms
|
WO2010028419A1
(en)
|
2008-09-09 |
2010-03-18 |
Orygen Research Centre |
Prevention of psychotic disorders and/or treatment of psychotic symptoms
|
US8060617B2
(en)
*
|
2008-12-19 |
2011-11-15 |
Cisco Technology, Inc. |
Reserving network resources during scheduling of meeting event
|
DK2596786T3
(en)
|
2009-02-10 |
2020-02-24 |
Amarin Pharmaceuticals Ie Ltd |
Use of eicosapentaenoic acid ethyl ester for the treatment of hypertriglyceridemia
|
GB0904300D0
(en)
|
2009-03-12 |
2009-04-22 |
Amarin Neuroscience Ltd |
Essential fatty acid compounds
|
NZ624963A
(en)
|
2009-04-29 |
2016-07-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
HUE051916T2
(en)
|
2009-04-29 |
2021-04-28 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition and methods of using same
|
SG177254A1
(en)
|
2009-06-15 |
2012-02-28 |
Ian Osterloh |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
SG10201405994UA
(en)
|
2009-09-23 |
2014-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
|
US8372465B2
(en)
|
2010-02-17 |
2013-02-12 |
Bunge Oils, Inc. |
Oil compositions of stearidonic acid
|
EP2542060B1
(en)
*
|
2010-03-04 |
2019-10-02 |
Amarin Pharmaceuticals Ireland Limited |
Compositions for treating and/or preventing cardiovascular disease
|
EP2593141B1
(en)
|
2010-07-16 |
2018-07-04 |
Atrium Medical Corporation |
Composition and methods for altering the rate of hydrolysis of cured oil-based materials
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
AU2011336856A1
(en)
|
2010-11-29 |
2013-07-04 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
WO2012083034A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Louis Sanfilippo |
Modulation of neurotrophic factors by omega-3 fatty acid formulations
|
US8951514B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
|
US9119826B2
(en)
|
2011-02-16 |
2015-09-01 |
Pivotal Therapeutics, Inc. |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
|
US8952000B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
|
US8715648B2
(en)
|
2011-02-16 |
2014-05-06 |
Pivotal Therapeutics Inc. |
Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
|
EP2540292A1
(en)
*
|
2011-06-28 |
2013-01-02 |
Nestec S.A. |
DHA and EPA in the reduction of oxidative stress
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
US9867880B2
(en)
|
2012-06-13 |
2018-01-16 |
Atrium Medical Corporation |
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
|
AU2013282394B2
(en)
|
2012-06-29 |
2018-04-26 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
JP2017506233A
(en)
|
2014-02-07 |
2017-03-02 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
Combination of creatine, omega-3 fatty acid, and citicoline
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
WO2016063959A1
(en)
*
|
2014-10-24 |
2016-04-28 |
日油株式会社 |
Antibody-drug complex having cyclic benzylidene acetal linker
|
ES2607715B1
(en)
*
|
2015-10-01 |
2018-01-17 |
Solutex Na, Lcc |
PROCESS FOR THE PREPARATION AND STABILIZATION OF EMULSIONS WITH OMEGA-3 THROUGH ISOMETRIC CRYSTAL NETWORKS OF CELLULOSE DERIVATIVES
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
TW201900160A
(en)
|
2017-05-19 |
2019-01-01 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
KR102296068B1
(en)
|
2018-09-24 |
2021-09-02 |
애머린 파마슈티칼스 아일랜드 리미티드 |
Methods of Reducing the Risk of a Cardiovascular Event in a Subject
|
KR20240012390A
(en)
|
2021-04-21 |
2024-01-29 |
애머린 파마슈티칼스 아일랜드 리미티드 |
How to Reduce Your Risk of Heart Failure
|